PRA Health Sciences - PRAH Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$165.21
+0 (0.00%)
Get New PRA Health Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRAH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRAH

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for PRA Health Sciences in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $165.21.

This chart shows the closing price for PRAH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in PRA Health Sciences. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2021Truist FinancialReiterated RatingBuy ➝ Hold$196.00 ➝ $175.00Low
5/10/2021Truist FinancialDowngradeBuy ➝ Hold$196.00 ➝ $175.00Medium
4/29/2021Credit Suisse GroupBoost TargetOutperform$159.00 ➝ $169.00Low
4/26/2021Robert W. BairdReiterated RatingOutperform ➝ Neutral$165.00N/A
4/20/2021Robert W. BairdDowngradeOutperform ➝ Neutral$165.00Low
3/19/2021MizuhoBoost Target$110.00 ➝ $155.00Low
3/15/2021KeyCorpReiterated RatingOverweight ➝ Sector WeightLow
2/25/2021Jefferies Financial GroupDowngradeBuy ➝ HoldLow
1/21/2021Robert W. BairdBoost TargetOutperform$130.00 ➝ $145.00Low
11/5/2020Credit Suisse GroupBoost TargetOutperform$120.00 ➝ $125.00High
8/10/2020UBS GroupBoost TargetNeutral$105.00 ➝ $111.00Medium
8/10/2020Bank of AmericaDowngradeBuy ➝ Underperform$110.00 ➝ $100.00Low
8/10/2020MizuhoBoost TargetNeutral ➝ In-Line$92.00 ➝ $108.00Low
8/10/2020CitigroupBoost TargetNeutral$90.00 ➝ $110.00Low
8/7/2020Credit Suisse GroupBoost TargetOutperform$113.00 ➝ $116.00Medium
5/5/2020UBS GroupLower TargetNeutral$103.00 ➝ $101.00Low
5/4/2020SunTrust BanksBoost TargetBuy$89.00 ➝ $103.00Low
5/4/2020Robert W. BairdLower TargetOutperform$106.00 ➝ $101.00Medium
5/1/2020Credit Suisse GroupLower TargetOutperform$122.00 ➝ $113.00High
5/1/2020William BlairDowngradeOutperform ➝ Market PerformHigh
4/28/2020UBS GroupLower TargetNeutral$116.00 ➝ $103.00Low
4/13/2020Wolfe ResearchDowngradeOutperform ➝ Market Perform$97.00Medium
4/9/2020CitigroupLower TargetNeutral$120.00 ➝ $90.00High
4/3/2020MizuhoLower TargetNeutral$95.00 ➝ $82.00High
3/26/2020BarclaysLower TargetOverweight$123.00 ➝ $114.00Medium
3/23/2020Jefferies Financial GroupLower TargetBuy$125.00 ➝ $89.00Low
3/17/2020SunTrust BanksLower TargetBuy$127.00 ➝ $89.00High
2/21/2020Robert W. BairdBoost TargetOutperform$122.00 ➝ $128.00High
1/10/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$130.00 ➝ $120.00High
1/6/2020CitigroupInitiated CoverageNeutral$120.00Medium
11/14/2019Wolfe ResearchUpgradePeer Perform ➝ Outperform$123.00Medium
9/19/2019The Goldman Sachs GroupInitiated CoverageBuy$126.00Low
9/6/2019Jefferies Financial GroupBoost TargetBuy$115.00 ➝ $120.00Low
9/4/2019BarclaysBoost TargetOverweight$115.00 ➝ $118.00High
7/2/2019SVB LeerinkReiterated RatingMarket PerformMedium
5/3/2019MizuhoSet TargetHold$100.00Low
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/22/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/19/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
PRA Health Sciences logo
PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. It operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that allow clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.
Read More

Today's Range

Now: $165.21
Low: $165.21
High: $165.21

50 Day Range

MA: $167.50
Low: $165.21
High: $174.52

52 Week Range

Now: $165.21
Low: $93.00
High: $175.95

Volume

57 shs

Average Volume

837,472 shs

Market Capitalization

$10.70 billion

P/E Ratio

50.52

Dividend Yield

N/A

Beta

1.31

Frequently Asked Questions

What sell-side analysts currently cover shares of PRA Health Sciences?

The following Wall Street research analysts have issued stock ratings on PRA Health Sciences in the last year: StockNews.com.
View the latest analyst ratings for PRAH.

What is the current price target for PRA Health Sciences?

0 Wall Street analysts have set twelve-month price targets for PRA Health Sciences in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for PRA Health Sciences in the next year.
View the latest price targets for PRAH.

What is the current consensus analyst rating for PRA Health Sciences?

PRA Health Sciences currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for PRAH.

What other companies compete with PRA Health Sciences?

How do I contact PRA Health Sciences' investor relations team?

PRA Health Sciences' physical mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company's listed phone number is (919) 786-8200 and its investor relations email address is [email protected]. The official website for PRA Health Sciences is www.prahs.com. Learn More about contacing PRA Health Sciences investor relations.